Management of side effects of mTOR inhibitors in tuberous sclerosis patients.

Management of side effects of mTOR inhibitors in tuberous sclerosis patients.

Item
http://www.wikidata.org/entity/Q38739340
mTOR and MAPK: from localized translation control to epilepsyDisulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Normalizing translation through 4E-BP prevents mTOR-driven cortical mislamination and ameliorates aberrant neuron integration.Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase ActivityTFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.
P2860

Management of side effects of mTOR inhibitors in tuberous sclerosis patients.

Item
http://www.wikidata.org/entity/Q38739340
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
@en
type
label
Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
@en
prefLabel
Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
@en
P2093
P304
P31
P356
10.1016/J.PHAREP.2016.01.005
P433
P478
P50
P577
P698